Zymera, Inc. is a privately held nanobiotechnology company pioneering the commercialization of self-illuminating red to near infrared (NIR) emitting nanocrystal technologies for preclinical in vivo imaging and as an analytical platform for molecular detection. The firm is offering high-quality reagents and materials intended for research use only. The BRET-Qdot® reagents are sold subject to an agreement between Life Technologies Corporation and Zymera, Inc. for specific FIELDS OF USE: (I) non-human in vivo imaging applications, (II) detection of antigens, (III) microscopy and automated or high content imaging, and (IV) quantification of signal intensities in cells and tissue samples.
